IL6 and metabolic dysfunction-associated steatotic liver disease: However, no statistically significant differences were observed between probiotics and synbiotics with respect to lipid markers total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), or inflammatory cytokines tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6).<h4>Conclusions</h4>Probiotics and synbiotics significantly improve liver enzymes and hepatic steatosis in patients with MASLD.